Type 2 diabetes mellitus impaired nasal immunity and increased the risk of hyposmia in COVID-19 mild pneumonia patients

Yi Zhao,Yujie Liu,Fangzheng Yi,Jun Zhang,Zhaohui Xu,Yehai Liu,Ye Tao
DOI: https://doi.org/10.1016/j.intimp.2021.107406
IF: 5.714
2021-04-01
International Immunopharmacology
Abstract:<p>In patients with COVID-19, type 2 diabetes mellitus (T2DM) can impair the function of nasal-associated lymphoid tissue (NALT) and result in olfactory dysfunction. Exploring the causative alterations of T2DM within the nasal mucosa and NALT could provide insight into the pathogenic mechanisms and bridge the gap between innate immunity and adaptive immunity for virus clearance. <u>Here, we designed a case-control study to compare the olfactory function (OF) among the groups of normal control (NC), COVID-19 mild pneumonia (MP), and MP patients with T2DM (MPT) after a 6-8 months' recovery, in which MPT had a higher risk of hyposmia than MP and NC. No significant difference was found between the MP and NC. This elevated risk of hyposmia indicated that T2DM increased COVID-19 susceptibility in the nasal cavity with unknown causations. Therefore, we used the T2DM animal model (db/db mice) to evaluate how T2DM increased COVID-19 associated susceptibilities in the nasal mucosa and lymphoid tissues. Db/db mice demonstrated upregulated microvasculature ACE2 expression and significant alterations in lymphocytes component of NALT. Specifically, db/db mice NALT had increased immune-suppressive TCRγδ</u><sup>±</sup><u>CD4<sup>-</sup>CD8<sup>-</sup> T and decreased immune-effective CD4</u><sup>±</sup><u>/CD8</u><sup>±</sup><u>TCRβ</u><sup>±</sup> <u>T cells and decreased mucosa-protective CD19</u><sup>±</sup> <u>B cells. These results indicated that T2DM could dampen the first-line defense of nasal immunity, and further mechanic studies of metabolic damage and NALT restoration should be one of the highest importance for COVID-19 healing.</u></p>
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to explore how type 2 diabetes mellitus (T2DM) affects the nasal immune function of patients with mild COVID - 19 pneumonia and increases the risk of olfactory disorder (hyposmia). Specifically, the research focuses on the following two aspects: 1. **Evaluating combined risks**: Evaluate the risk of olfactory disorder in patients with mild COVID - 19 pneumonia under the combined effect of T2DM and SARS - CoV - 2 infection. 2. **Mechanism research**: Use the T2DM animal model (db/db mice) to reveal how T2DM increases the susceptibility of COVID - 19 in the nasal mucosa and nasal - associated lymphoid tissue (NALT), especially by the changes in the expression of ACE2 and TMPRSS2 and the alteration of lymphocyte types to increase the risk of olfactory disorder. ### Research background - **COVID - 19 and olfactory disorder**: SARS - CoV - 2 infection can attack the olfactory nerve or the surrounding mucosal tissue, resulting in olfactory disorder (OD). This disorder usually exists 2 - 3 days before the appearance of pneumonia symptoms. - **The influence of T2DM**: T2DM not only increases the susceptibility to COVID - 19, but may also aggravate the severity of the disease and affect the recovery of olfactory function. - **The role of NALT**: NALT is the tertiary lymphoid tissue in the nasopharynx, responsible for initiating the innate immune response, recognizing and presenting specific antigens, and inducing the adaptive immune response. T2DM may change the function of NALT, thereby increasing the risk of disease susceptibility and olfactory disorder. ### Main findings 1. **T2DM increases the risk of olfactory disorder**: - The study found that among patients with mild COVID - 19 pneumonia, patients with combined T2DM (MPT group) had a higher risk of olfactory disorder than patients with simple mild COVID - 19 pneumonia (MP group) and the normal control group (NC group). - Specifically, the TDI score of the MPT group was significantly lower than that of the MP group and the NC group, and the incidence of olfactory disorder in the MPT group was significantly higher than that in the other two groups. 2. **The influence of T2DM on NALT**: - The db/db mouse model showed that T2DM led to the up - regulation of ACE2 expression in NALT, especially in microvascular endothelial cells. - At the same time, T2DM led to the down - regulation of TMPRSS2 expression, especially in mucosal epithelial cells. - The number of CD4 + and CD8 + T cells and CD19 + B cells in NALT decreased, while the number of immunosuppressive TCRγδ+CD4 - CD8 - T cells increased. 3. **Potential mechanisms**: - The up - regulation of ACE2 expression may promote the invasion of SARS - CoV - 2, leading to the apoptosis or necrosis of endothelial cells, and then affecting the blood supply of olfactory fibers, causing hypoxic damage. - The down - regulation of TMPRSS2 expression may lead to mucosal atrophy, further damaging the immune response and the regeneration of olfactory nerves. ### Conclusion This study reveals that T2DM increases the risk of olfactory disorder in patients with mild COVID - 19 pneumonia by affecting the immune function of NALT and the expression of ACE2/TMPRSS2. These findings provide a new perspective for understanding the interaction between T2DM and COVID - 19, and emphasize the importance of metabolic damage and NALT repair in the treatment of COVID - 19.